39 citations
,
April 2020 in “Clinical, Cosmetic and Investigational Dermatology” This review discusses the unique characteristics and disorders of Asian hair, emphasizing the need for more comprehensive studies in this area.
4 citations
,
September 2019 in “Journal of cosmetic dermatology” This study found that after 24 weeks of bimatoprost 0.01% treatment, significant improvements in the density and diameter of eyebrow hair were observed, most notably in the tail section of the eyebrow.
117 citations
,
August 2019 in “Drug Design Development and Therapy” This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.
10 citations
,
June 2019 in “Dermatologic therapy” In this study, treatment with DPCP alone was more effective for hair regrowth and presented fewer side effects in chronic extensive alopecia areata compared to combination therapy with DPCP and anthralin.
20 citations
,
June 2019 in “Archives of dermatological research” In this study, combination therapy with DPCP and anthralin promoted hair regrowth in 40.62% of alopecia areata patients who were unresponsive to DPCP alone, with response improving over longer treatment durations.
29 citations
,
April 2019 in “Lasers in Medical Science” This study found that combining fractional erbium-glass laser therapy with topical minoxidil significantly improved hair density and diameter in men with androgenetic alopecia compared to using minoxidil alone over a 24-week period, with no serious adverse events reported.
16 citations
,
January 2019 in “Skin appendage disorders” This study used a network meta-analysis to compare alopecia areata treatments, finding that intralesional corticosteroids are most effective for mild cases, while diphenylcyclopropenone ranks highest for moderate to severe cases; further research on oral tofacitinib is needed.
45 citations
,
December 2018 in “Lasers in Medical Science” In a 24-week randomized trial, this study found that the RAMACAP laser helmet significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, although limitations included a small sample size and potential issues with the control used.
36 citations
,
September 2018 in “American Journal of Clinical Dermatology” This study found that a topical combination of 0.25% finasteride and 3% minoxidil may increase hair diameter more effectively than 3% minoxidil alone in postmenopausal women with female pattern hair loss.
26 citations
,
August 2018 in “American Journal of Clinical Dermatology” This review discusses the clinical characteristics of alopecia in cancer patients, highlighting its potential role as an associated finding or diagnostic clue, but reports no new clinical results.
89 citations
,
August 2018 in “JAMA Dermatology” This study found that the level of expected therapeutic regrowth significantly affected hair regrowth outcomes in contact immunotherapy for alopecia areata, suggesting implications for patient education and adherence.
53 citations
,
July 2018 in “Drug design, development and therapy” This review summarizes existing evidence on the efficacy and safety of JAK inhibitors for treating alopecia areata and emphasizes the need for improved topical formulations.
34 citations
,
February 2018 in “Drug Design Development and Therapy” This source reports that bimatoprost, a medication approved for eyelash growth, has shown efficacy in treating eyebrow hypotrichosis, suggesting it as a noninvasive, effective, and well-tolerated option for enhancing eyebrow hair.
8 citations
,
January 2018 in “Journal of the American Academy of Dermatology” This study found that maintenance treatment with diphenylcyclopropenone was associated with a lower relapse rate in alopecia areata patients, highlighting the importance of adjusting treatment intervals post-improvement.
10 citations
,
January 2018 in “Postępy Dermatologii i Alergologii” This study found that 21 out of 39 patients with alopecia areata experienced more than 50% hair regrowth after six months of DPCP treatment, with better outcomes observed in those treated at 3-week intervals compared to weekly intervals.
182 citations
,
December 2017 in “Journal of the American Academy of Dermatology” This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.
30 citations
,
December 2017 in “Clinical, Cosmetic and Investigational Dermatology” This study found significant differences in hair density, non-vellus hair diameter, and percentage of miniaturized hair between normal women and those with female pattern hair loss, particularly in the midscalp and parietal areas.
27 citations
,
September 2017 in “Archives of Dermatological Research” In this study, topical tofacitinib significantly increased hair regrowth in mice compared to minoxidil or vehicle, potentially due to elevated VEGF levels and reduced inflammation.
21 citations
,
June 2017 in “Journal of The American Academy of Dermatology” This study reviewed existing articles to assess the efficacy of topical diphenylcyclopropenone immunotherapy for alopecia areata, but it did not report new clinical results.
44 citations
,
April 2017 in “International Journal of Dermatology” This study reviewed treatment options for alopecia areata totalis and universalis, finding no completely effective therapy. Promising treatments with quality data include diphenylcyclopropenone, squaric acid dibutylester, and photodynamic therapy, but larger, high-quality trials are needed.
37 citations
,
January 2017 in “International Journal of Dermatology” This study found that trichoscopic features like exclamation mark hairs and angulated hairs were more indicative of alopecia areata in an Asian population, while features like broken hairs of different lengths and flame hairs were more common in trichotillomania.
38 citations
,
January 2017 in “PPAR Research” This review discusses the role of PPAR-γ in the pathogenesis of primary cicatricial alopecia, including its involvement in lichen planopilaris and treatment trials using PPAR-agonists, and reports no new clinical results.
6 citations
,
October 2016 in “Pediatric Dermatology” This case report describes a unique instance of a 6-year-old girl developing angioedema after treatment with squaric acid dibutylester for alopecia areata.
95 citations
,
July 2016 in “Journal of The American Academy of Dermatology” This review concluded that patients with alopecia areata consistently show poor health-related quality of life scores, similar to those in other chronic skin diseases like atopic dermatitis and psoriasis.
9 citations
,
April 2016 in “Australasian journal of dermatology” This study suggests that adding imiquimod to diphenylcyclopropenone treatment significantly improves outcomes for alopecia areata patients who initially do not respond to diphenylcyclopropenone alone.
128 citations
,
February 2016 in “British Journal of Dermatology” This study found that patients with alopecia areata experience significant impairments in health-related quality of life, notably affecting mental health, according to various quality of life assessment tools.
29 citations
,
January 2016 in “International Journal of Dermatology” This study reports that the duration of hair loss is positively associated with the severity of central centrifugal cicatricial alopecia in African-American women.
27 citations
,
December 2015 in “Clinical and Experimental Dermatology” This study found that hair regrowth occurred in 72.2% of alopecia areata patients treated with diphencyprone, with disease extent at baseline and duration affecting outcomes.
41 citations
,
November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.
44 citations
,
February 2015 in “Journal of the American Academy of Dermatology” This study found that combination therapy with diphenylcyclopropenone and anthralin was more effective for complete hair regrowth in chronic extensive alopecia areata than diphenylcyclopropenone alone, despite more common side effects.
15 citations
,
January 2015 in “Dermatitis” This review discusses the efficacy and safety of topical sensitizers for treating alopecia areata and reports no new clinical results; it emphasizes advancements in pediatric use, molecular mechanisms, and targeted delivery methods.
5 citations
,
January 2014 in “Hospital pharmacy” This case report suggests that frequent application of diphenylcyclopropenone 2% solution to the scalp for alopecia areata may lead to scalp angioedema.
79 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” This article proposes that alopecia areata may be caused by immune attacks on hair follicles after an immune privilege collapse, suggesting new therapeutic approaches targeting this immune response pattern.
37 citations
,
September 2012 in “Archives of dermatology” Diphencyprone can help some children with alopecia areata regrow hair, but it often causes side effects.
218 citations
,
April 2012 in “British Journal of Dermatology” This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.
717 citations
,
June 2010 in “Nature” This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.
36 citations
,
May 2005 in “BMC dermatology” This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.
20 citations
,
February 2004 in “Clinical & Experimental Immunology” This study suggests that long-term treatment with the contact sensitizer SADBE in mice may reduce leucocyte traffic in alopecia areata through impaired leucocyte extravasation.
182 citations
,
October 2003 in “British Journal of Dermatology” These guidelines for alopecia areata management, prepared by the British Association of Dermatologists, provide evidence-based treatment recommendations and insights into the condition's epidemiology, diagnosis, and investigation.
60 citations
,
September 2001 in “British journal of dermatology/British journal of dermatology, Supplement” This review discusses the use of contact sensitizers in topical immunotherapy for conditions like alopecia areata and viral warts, focusing on treatment methods, efficacy, and potential adverse effects, and reports no new clinical results.
127 citations
,
January 2000 in “Journal of Investigative Dermatology” This study found that pro-inflammatory cytokines and apoptotic mechanisms, specifically involving granzyme B and Fas pathways, are associated with chronic alopecia areata, indicating their potential role in the disease's persistence.
132 citations
,
November 1998 in “Journal of the American Academy of Dermatology” This review evaluates the efficacy and safety of topical sensitizers in treating alopecia areata but reports no new clinical findings.
41 citations
,
November 1993 in “Journal of The American Academy of Dermatology” This study found that DPCP treatment led to cosmetically acceptable hair regrowth in 38% of patients with chronic severe alopecia areata, while adding 5% minoxidil showed no significant clinical benefit.
84 citations
,
August 1991 in “British Journal of Dermatology” This study found that 67% of children treated with diphencyprone for alopecia areata or alopecia totalis regrew scalp hair, with 33% achieving complete regrowth.
36 citations
,
March 1989 in “British journal of dermatology/British journal of dermatology, Supplement” In this study, the authors compared topical diphencyprone and tretinoin gel for treating alopecia totalis and universalis, but the abstract does not report any definitive clinical results.
42 citations
,
August 1987 in “Archives of Dermatology” In this study, 28.5% of patients with extensive alopecia areata had complete hair regrowth during treatment with squaric acid dibutylester, with outcomes linked to shorter alopecia duration and prompt dermatitis development.
50 citations
,
July 1981 in “Archives of Dermatology” This study found that applying dinitrochlorobenzene (DNCB), a contact allergen, led to hair regrowth in patients with alopecia areata, while croton oil did not have the same effect.
